| Variable |
NVP group SVR/no. (%) |
LPV/r group SVR/no. (%) |
p univariate |
| Baseline HCV RNA level |
|
|
|
| > 600000 IU/mL |
18/31 (58) |
21/68 (31) |
0.01 |
| < 600000 IU/mL |
22/40 (55) |
14/26 (53) |
0.8 |
| Liver fibrosis |
|
|
|
| Advanced (F3-F4) |
6/10 (60) |
13/36 (36) |
0.2 |
| Non-advanced (F0-F2) |
18/37 (47) |
11/33 (33) |
0.2 |
| Cirrhosis |
|
|
|
| Yes |
3/3 (100) |
8/22 (36) |
0.07 |
| No |
21/44 (47) |
16/47 (34) |
0.2 |
| Baseline LDL-cholesterol |
|
|
|
| > 100 mg/dL |
16/25 (64) |
10/23 (43) |
0.1 |
| < 100 mg/dL |
14/25 (56) |
15/47 (32) |
0.04 |
| Baseline undetectable HIV viral load |
|
|
|
| Yes |
39/68 (57) |
30/77 (39) |
0.02 |
| No |
1/3 (33) |
5/17 (29) |
0.9 |
| Time from starting NVP or LPV/r to beginning HCV therapy† |
|
|
|
| < 27 months |
14/25 (56) |
21/57 (36) |
0.05 |
| > 27 months |
26/46 (56) |
14/37 (37) |
0.05 |
| Time with undetectable HIV viral load before starting HCV therapy†* |
|
|
|
| < 42 months |
19/26 (73) |
17/44 (39) |
0.009 |
| > 42 months |
21/42 (50) |
12/33 (37) |
0.2 |
†Categorized by median.*Excluding patients with detectable HIV viral load at baseline. NVP: nevirapine. LPV/r: lopinavir/ritonavir. |
